Compare Stocks: SLN, AMLX, KLRA, and AGIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$32.75 -6.5%	$34.45	$22.24 ▼ $46.00	$2.08B	0.54	1.02 million shs	3.13 million shs
AMLX Amylyx Pharmaceuticals	$20.75 +5.2%	$16.41	$7.48 ▼ $20.94	$2.19B	-0.2	1.51 million shs	3.54 million shs
KLRA Kailera Therapeutics	$17.08 +1.2%	$20.23	$16.50 ▼ $28.23	$2.19B	N/A	764,849 shs	568,895 shs
SLN Silence Therapeutics	$11.62 +0.6%	$8.76	$4.19 ▼ $12.19	$548.87M	1.38	492,031 shs	769,573 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	-6.46%	-9.73%	-11.75%	+16.96%	-12.76%
AMLX Amylyx Pharmaceuticals	+5.17%	+17.96%	+15.62%	+29.69%	+160.35%
KLRA Kailera Therapeutics	+1.18%	-1.84%	-22.47%	-31.68%	+1,707,999,900.00%
SLN Silence Therapeutics	+0.61%	+1.48%	+5.83%	+58.96%	+88.94%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$32.75 -6.5%	$34.45	$22.24 ▼ $46.00	$2.08B	0.54	1.02 million shs	3.13 million shs
AMLX Amylyx Pharmaceuticals	$20.75 +5.2%	$16.41	$7.48 ▼ $20.94	$2.19B	-0.2	1.51 million shs	3.54 million shs
KLRA Kailera Therapeutics	$17.08 +1.2%	$20.23	$16.50 ▼ $28.23	$2.19B	N/A	764,849 shs	568,895 shs
SLN Silence Therapeutics	$11.62 +0.6%	$8.76	$4.19 ▼ $12.19	$548.87M	1.38	492,031 shs	769,573 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	-6.46%	-9.73%	-11.75%	+16.96%	-12.76%
AMLX Amylyx Pharmaceuticals	+5.17%	+17.96%	+15.62%	+29.69%	+160.35%
KLRA Kailera Therapeutics	+1.18%	-1.84%	-22.47%	-31.68%	+1,707,999,900.00%
SLN Silence Therapeutics	+0.61%	+1.48%	+5.83%	+58.96%	+88.94%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.40	Hold	$40.38	23.28% Upside
AMLX Amylyx Pharmaceuticals	2.90	Moderate Buy	$24.63	18.67% Upside
KLRA Kailera Therapeutics	3.00	Buy	$42.75	150.29% Upside
SLN Silence Therapeutics	2.83	Moderate Buy	$55.00	373.32% Upside

Current Analyst Ratings Breakdown

Latest SLN, AMLX, KLRA, and AGIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2026	AGIO Agios Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/30/2026	AGIO Agios Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$52.00 ➝ $55.00
7/21/2026	AGIO Agios Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$54.00 ➝ $52.00
7/20/2026	AMLX Amylyx Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$21.00 ➝ $24.00
7/17/2026	SLN Silence Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/7/2026	AGIO Agios Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$28.00 ➝ $32.00
7/7/2026	AGIO Agios Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$36.00 ➝ $41.00
7/7/2026	AGIO Agios Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$40.00 ➝ $46.00
6/25/2026	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$30.00 ➝ $40.00
6/24/2026	AGIO Agios Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
6/24/2026	SLN Silence Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight

(Data available from 7/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$54.03M	36.05	N/A	N/A	$20.46 per share	1.60
AMLX Amylyx Pharmaceuticals	$87.37M	26.41	N/A	N/A	$2.78 per share	7.46
KLRA Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	$839K	654.20	N/A	N/A	$1.32 per share	8.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	-$412.78M	-$7.25	N/A	N/A	N/A	-639.84%	-34.11%	-31.66%	N/A
AMLX Amylyx Pharmaceuticals	-$144.74M	-$1.50	N/A	N/A	N/A	N/A	-55.69%	-50.73%	8/6/2026 (Estimated)
KLRA Kailera Therapeutics	N/A	-$3,650.00	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	-$88.61M	-$1.59	N/A	N/A	N/A	-8,943.86%	-105.34%	-52.79%	8/6/2026 (Estimated)

Latest SLN, AMLX, KLRA, and AGIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	AMLX Amylyx Pharmaceuticals	-$0.36	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	SLN Silence Therapeutics	-$0.1387	N/A	N/A	N/A	$1.17 million	N/A
7/30/2026	Q2 2026	AGIO Agios Pharmaceuticals	-$1.6548	-$1.69	-$0.0352	-$1.69	$26.40 million	$44.75 million
5/26/2026	Q1 2026	KLRA Kailera Therapeutics	N/A	-$3,650.00	N/A	-$3,650.00	N/A	N/A
5/8/2026	Q1 2026	SLN Silence Therapeutics	-$0.1850	-$0.32	-$0.1350	-$0.33	$1.26 million	$0.42 million
5/7/2026	Q1 2026	AMLX Amylyx Pharmaceuticals	-$0.34	-$0.37	-$0.03	-$0.37	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KLRA Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	14.19	13.59
AMLX Amylyx Pharmaceuticals	N/A	17.85	17.85
KLRA Kailera Therapeutics	N/A	N/A	N/A
SLN Silence Therapeutics	N/A	9.83	9.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
AMLX Amylyx Pharmaceuticals	95.84%
KLRA Kailera Therapeutics	N/A
SLN Silence Therapeutics	98.73%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	5.40%
AMLX Amylyx Pharmaceuticals	10.90%
KLRA Kailera Therapeutics	N/A
SLN Silence Therapeutics	3.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	59.47 million	56.26 million	Optionable
AMLX Amylyx Pharmaceuticals	200	111.19 million	99.07 million	Optionable
KLRA Kailera Therapeutics	145	129.57 million	N/A	N/A
SLN Silence Therapeutics	100	47.24 million	45.82 million	Not Optionable

SLN, AMLX, KLRA, and AGIO Headlines

Recent News About These Companies

Silence Therapeutics (SLN) to Post Earnings on Thursday

July 30 at 4:40 AM | marketbeat.com

ADAR1 Capital Management LLC Buys 148,514 Shares of Silence Therapeutics PLC Sponsored ADR $SLN

July 30 at 3:03 AM | marketbeat.com

Silence Therapeutics (NASDAQ:SLN) Sees Large Volume Increase - Still a Buy?

July 28 at 1:59 PM | marketbeat.com

Silence Therapeutics (NASDAQ:SLN) Reaches New 12-Month High - Time to Buy?

July 23, 2026 | marketbeat.com

Silence Therapeutics (NASDAQ:SLN) Stock Price Up 6.9% - Here's Why

July 22, 2026 | marketbeat.com

Silence Therapeutics (NASDAQ:SLN) Sets New 52-Week High - Here's Why

July 17, 2026 | marketbeat.com

SLN Stock Skyrockets 107% in Six Months: Here's What You Need to Know

July 16, 2026 | zacks.com

Silence Therapeutics (SLN) Moves 7.2% Higher: Will This Strength Last?

July 16, 2026 | zacks.com

Silence Therapeutics (NASDAQ:SLN) Shares Up 10% - Here's What Happened

July 15, 2026 | marketbeat.com

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Average Rating of "Moderate Buy" from Brokerages

July 12, 2026 | marketbeat.com

Silence Therapeutics: PV Data Could Wake The Stock (Initiating Buy)

July 12, 2026 | seekingalpha.com

Silence Therapeutics plc (SLN) Initiated at Overweight as Analyst Highlights siRNA Pipeline Potential

June 30, 2026 | insidermonkey.com

Silence Therapeutics (SLN) Surges 26.0%: Is This an Indication of Further Gains?

June 25, 2026 | zacks.com

Silence: 'Buy' Zerlasiran Program Shift And Divesiran Results August 2026

June 12, 2026 | seekingalpha.com

Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

June 11, 2026 | businesswire.com

Silence Therapeutics (SLN) Receives a Buy from H.C. Wainwright

May 27, 2026 | theglobeandmail.com

Silence Therapeutics to Participate in Jefferies Global Healthcare Conference

May 27, 2026 | businesswire.com

Silence Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:SLN

May 18, 2026 | benzinga.com

Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference

May 13, 2026 | pharmiweb.comP

Silence Therapeutics highlights recent business achievements and reports first quarter 2026 financial results

May 7, 2026 | msn.com

Silence Therapeutics (SLN) Soars 19.0%: Is Further Upside Left in the Stock?

April 16, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLN, AMLX, KLRA, and AGIO Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$32.75 -2.26 (-6.46%)

Closing price 07/30/2026 04:00 PM Eastern

Extended Trading

$30.95 -1.80 (-5.50%)

As of 07:11 AM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Amylyx Pharmaceuticals NASDAQ:AMLX

$20.75 +1.02 (+5.17%)

Closing price 07/30/2026 04:00 PM Eastern

Extended Trading

$20.97 +0.22 (+1.06%)

As of 07:55 AM Eastern

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Kailera Therapeutics NASDAQ:KLRA

$17.08 +0.20 (+1.18%)

As of 07/30/2026 03:58 PM Eastern

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives. With our obesity-first focus, we have built a diversified pipeline of product candidates specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate that we believe offers the potential for the greatest weight loss. We are rapidly progressing four clinical-stage product candidates, leveraging multiple glucagon-like peptide-1, or GLP-1, based mechanisms of action and routes of administration. Our lead product candidate, ribupatide (also known as KAI-9531), is currently being evaluated in global Phase 3 trials as a once-weekly injectable GLP-1/glucose-dependent insulinotropic polypeptide, or GIP, receptor dual agonist peptide that we believe offers the potential for the greatest weight loss compared to all obesity management medications currently marketed or in development with a tolerability profile that is class-like or better. We are expanding our ribupatide franchise by developing a once-daily oral tablet formulation, oral ribupatide, based on the same peptide as injectable ribupatide, to provide a convenient oral option with the potential for highly differentiated tolerability with compelling weight loss among oral treatments. Additionally, we are advancing a second oral product candidate, KAI-7535, a once-daily small molecule GLP-1 receptor agonist with the potential to improve on the clinical profile of existing oral treatments. Finally, we are developing KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist, that leverages an incremental mechanism to potentially deliver compelling weight loss, improved liver fat reduction and a differentiated tolerability profile. KAI-4729 is based on a different peptide than injectable ribupatide and oral ribupatide. Obesity is a chronic, complex disease characterized by the accumulation of excessive body fat, resulting in significant negative impacts on health and quality of life. The most severely impacted patient population, people with a body mass index, or BMI, of 35 kg/m2 or greater, which we refer to as a BMI of 35+, represents the fastest growing and largest segment of this population, with half of U.S. adults with obesity expected to have a BMI of 35+ by 2030. While the approvals of GLP-1-based obesity management medications have changed the landscape of obesity management, there remains a critical need for medications offering greater weight loss, especially for those living with a higher BMI. For example, in the SURMOUNT-1 Phase 3 clinical trial, the majority of patients who had a baseline BMI of 35+ and were treated with tirzepatide, the most prescribed weight loss medicine today, were still living with obesity at the end of treatment. Both physicians and patients have identified expected weight loss as a primary treatment goal, with the magnitude of weight reduction serving as a crucial driver in therapy selection. We believe that injectable treatments will remain foundational for patients needing significant weight reduction. Meanwhile, for patients with a lower BMI, lower incidences of gastrointestinal side effects may be needed to achieve optimal weight loss and treatment persistence, and we believe oral treatments can unlock adoption for those with more modest weight loss needs, while also supporting the chronic treatment journey of those living with higher BMIs. We were originally incorporated under the laws of the State of Delaware on May 8, 2024 under the name Hercules CM Newco, Inc. We changed our name to Kailera Therapeutics, Inc. on August 22, 2024. Our principal executive offices are located in Waltham, Massachusetts.

Silence Therapeutics NASDAQ:SLN

$11.62 +0.07 (+0.61%)

Closing price 07/30/2026 04:00 PM Eastern

Extended Trading

$11.40 -0.22 (-1.89%)

As of 07:15 AM Eastern

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLN, AMLX, KLRA, and AGIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLN, AMLX, KLRA, and AGIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLN, AMLX, KLRA, and AGIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLN, AMLX, KLRA, and AGIO Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

Amylyx Pharmaceuticals NASDAQ:AMLX

Kailera Therapeutics NASDAQ:KLRA

Silence Therapeutics NASDAQ:SLN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLN, AMLX, KLRA, and AGIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLN, AMLX, KLRA, and AGIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLN, AMLX, KLRA, and AGIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLN, AMLX, KLRA, and AGIO Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

Amylyx Pharmaceuticals NASDAQ:AMLX

Kailera Therapeutics NASDAQ:KLRA

Silence Therapeutics NASDAQ:SLN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools